Register entry
- Registered sites
- 0
- Active NDC listings
- 17
- Live patents
- 28
- Exclusivities
- 2
- Shortage listings
- 1
- Countries
- 0
Alert
Drug shortage listings
1| Drug | Presentation | Status | Availability | Posted / updated |
|---|---|---|---|---|
| Triamcinolone Acetonide InjectionOphthalmology | Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01) | Resolved | - | 27 Sept 202131 Jul 2026 |
Catalogue
Drug listings by form and route
1717 active NDC listings: 16 human prescription drug, 1 human otc drug. By marketing category: NDA 15, BLA 1, OTC MONOGRAPH DRUG 1.
| Dosage form | NDCs |
|---|---|
| suspension/ drops | 5 |
| solution/ drops | 4 |
| for suspension | 2 |
| emulsion | 1 |
| for solution | 1 |
| gel | 1 |
| injection, solution | 1 |
| injection, suspension | 1 |
| suspension | 1 |
| Route | NDCs |
|---|---|
| ophthalmic | 16 |
| intravitreal | 1 |
| topical | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| harrow eye, llc | 17 |
Exclusivity
Patents and exclusivities
28| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 7834059 | NEVANACnepafenac | use | Jan 2027 |
| 8298568 | VERKAZIAcyclosporine | product | Nov 2027 |
| 8101582 | TOBRADEX STdexamethasone; tobramycin | product | Dec 2027 |
| 8450287 | TOBRADEX STdexamethasone; tobramycin | product | Dec 2027 |
| 7795316 | TOBRADEX STdexamethasone; tobramycin | product | Aug 2028 |
| 8211880 | TRIESENCEtriamcinolone acetonide | use | Mar 2029 |
| 8450311 | MOXEZAmoxifloxacin hydrochloride | product | May 2029 |
| 9114168 | MOXEZAmoxifloxacin hydrochloride | product | May 2029 |
| 9132071 | VERKAZIAcyclosporine | product | Jun 2029 |
| 8128960 | TRIESENCEtriamcinolone acetonide | product | Dec 2029 |
| 8829005 | ZERVIATEcetirizine hydrochloride | use | Mar 2030 |
| 9750684 | ZERVIATEcetirizine hydrochloride | product | Mar 2030 |
| 9993471 | ZERVIATEcetirizine hydrochloride | use | Mar 2030 |
| 8829005*PED | ZERVIATEcetirizine hydrochloride | use | Sept 2030 |
| 9662398 | ILEVROnepafenac | product | Dec 2030 |
| 8614178 | VEVYEcyclosporine | product | Dec 2030 |
| 8921337 | ILEVROnepafenac | product | Mar 2032 |
| 9254286 | ZERVIATEcetirizine hydrochloride | product | Jul 2032 |
| 9254286*PED | ZERVIATEcetirizine hydrochloride | use | Jan 2033 |
| 10588913 | BYQLOVIclobetasol propionate | product | May 2036 |
| 11376262 | BYQLOVIclobetasol propionate | product | May 2036 |
| 12496326 | VEVYEcyclosporine | use | Sept 2036 |
| 10813976 | VEVYEcyclosporine | product | Sept 2037 |
| 10792271 | IHEEZOchloroprocaine hydrochloride | product | Sept 2038 |
| 11154513 | VEVYEcyclosporine | product | Nov 2038 |
| 11969403 | IHEEZOchloroprocaine hydrochloride | product | May 2039 |
| 11413323 | VEVYEcyclosporine | use | Oct 2039 |
| 12059449 | VEVYEcyclosporine | product | Apr 2042 |
| Product | Exclusivity | Until |
|---|---|---|
| BYQLOVICLOBETASOL PROPIONATE | NP New product | Mar 2027 |
| VERKAZIACYCLOSPORINE | ODE-358 Orphan drug | Jun 2028 |
Catalogue
Marketed products
17| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| BYQLOVI | clobetasol propionate | for suspension, ophthalmic | 82667-021NDA |
| Byooviz | ranibizumab-nuna | injection, solution, intravitreal | 82667-018BLA |
| FRESHKOTE PRESERVATIVE FREE LUBRICANT EYE DROPS | povidone, polyvinyl alcohol solution | solution/ drops, ophthalmic | 82667-013OTC MONOGRAPH DRUG |
| Flarex | fluorometholone acetate | suspension/ drops, ophthalmic | 82667-010NDA |
| IHEEZO | chloroprocaine hydrochloride ophthalmic gel | gel, ophthalmic | 82667-300NDA |
| ILEVRO | nepafenac | suspension/ drops, ophthalmic | 82667-400NDA |
| IOPIDINE 1% | apraclonidine hydrochloride ophthalmic solution | solution/ drops, ophthalmic | 82667-200NDA |
| MAXIDEX | dexamethasone | for suspension, ophthalmic | 82667-600NDA |
| Maxitrol | neomycin sulfate, polymyxin b sulfate and dexamethasone | suspension, ophthalmic | 82667-100NDA |
| NATACYN | natamycin | suspension/ drops, ophthalmic | 82667-012NDA |
| NEVANAC | nepafenac | suspension/ drops, ophthalmic | 82667-500NDA |
| TRIESENCE | triamcinolone acetonide | injection, suspension, ophthalmic | 82667-800NDA |
| Tobradex ST | tobramycin / dexamethasone | suspension/ drops, ophthalmic | 82667-011NDA |
| VEVYE | cyclosporine ophthalmic solution | solution/ drops, ophthalmic | 82667-900NDA |
| VIGAMOX | moxifloxacin hydrochloride | solution/ drops, ophthalmic | 82667-700NDA |
| Verkazia | cyclosporine | emulsion, ophthalmic, topical | 82667-014NDA |
| ZERVIATE | cetirizine | for solution, ophthalmic | 82667-015NDA |
Compare
Other companies listing nepafenac
- Novartis Pharmaceuticals Corporation20 sites · 210 NDC
Enquiry
Common questions
- Is Harrow Eye, LLC FDA approved?
- Harrow Eye, LLC holds no registered establishment of its own; 17 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Harrow Eye, LLC make?
- 17 products are listed under Harrow Eye, LLC in the openFDA NDC Directory, most often as suspension/ drops; solution/ drops; for suspension. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.